ALZN vs. ACHL, AWH, SNSE, LABP, HOWL, IMAB, RAPT, TELO, KPTI, and ADAG
Should you be buying Alzamend Neuro stock or one of its competitors? The main competitors of Alzamend Neuro include Achilles Therapeutics (ACHL), Aspira Women's Health (AWH), Sensei Biotherapeutics (SNSE), Landos Biopharma (LABP), Werewolf Therapeutics (HOWL), I-Mab (IMAB), RAPT Therapeutics (RAPT), Telomir Pharmaceuticals (TELO), Karyopharm Therapeutics (KPTI), and Adagene (ADAG). These companies are all part of the "medical" sector.
Achilles Therapeutics (NASDAQ:ACHL) and Alzamend Neuro (NASDAQ:ALZN) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, dividends, institutional ownership, community ranking and analyst recommendations.
Achilles Therapeutics received 13 more outperform votes than Alzamend Neuro when rated by MarketBeat users. However, 100.00% of users gave Alzamend Neuro an outperform vote while only 54.84% of users gave Achilles Therapeutics an outperform vote.
Achilles Therapeutics currently has a consensus target price of $4.00, suggesting a potential upside of 382.57%. Given Alzamend Neuro's higher probable upside, equities analysts clearly believe Achilles Therapeutics is more favorable than Alzamend Neuro.
56.4% of Achilles Therapeutics shares are owned by institutional investors. Comparatively, 49.6% of Alzamend Neuro shares are owned by institutional investors. 5.4% of Achilles Therapeutics shares are owned by company insiders. Comparatively, 10.6% of Alzamend Neuro shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Alzamend Neuro is trading at a lower price-to-earnings ratio than Achilles Therapeutics, indicating that it is currently the more affordable of the two stocks.
Alzamend Neuro's return on equity of -42.95% beat Achilles Therapeutics' return on equity.
In the previous week, Achilles Therapeutics and Achilles Therapeutics both had 3 articles in the media. Alzamend Neuro's average media sentiment score of 1.44 beat Achilles Therapeutics' score of 0.46 indicating that Achilles Therapeutics is being referred to more favorably in the media.
Achilles Therapeutics has a beta of 1.32, indicating that its share price is 32% more volatile than the S&P 500. Comparatively, Alzamend Neuro has a beta of 0.03, indicating that its share price is 97% less volatile than the S&P 500.
Summary
Achilles Therapeutics beats Alzamend Neuro on 9 of the 13 factors compared between the two stocks.
Get Alzamend Neuro News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALZN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ALZN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Alzamend Neuro Competitors List
Related Companies and Tools
Free ALZN Stock Alerts